Biomarker evaluation in phase I clinical trials of selective PI3K and PI3k/mTOR inhibitors

被引：0

作者：

Spoerke, Jill ^{[1
]}

Desai, Rupal ^{[1
]}

Patel, Rajesh ^{[1
]}

Fredrickson, Jill ^{[1
]}

Wang, Yulei ^{[1
]}

Levy, Gallia ^{[1
]}

Gendreau, Steve ^{[1
]}

Lauchle, Jennifer ^{[1
]}

Derynck, Mika ^{[1
]}

Raja, Rajiv ^{[1
]}

Koeppen, Hartmut ^{[1
]}

Hampton, Garret ^{[1
]}

Yan, Yibing ^{[1
]}

Lackner, Mark R. ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

来源：

CANCER RESEARCH | 2013年 / 73卷 / 08期

关键词：

D O I：

10.1158/1538-7445.AM2013-4567

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4567

引用

页数：1

共 50 条

[1] Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
Spoerke, Jill
O'Brien, Carol
Wu, Jenny
Desai, Rupal
Patel, Rajesh
Raja, Rajiv
Koeppen, Hartmut
Amler, Lukas
Hampton, Garret
Yan, Yibing
Lackner, Mark R.
[J]. CANCER RESEARCH, 2012, 72
[2] Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
Nakanishi, Yoshito
Spoerke, Jill M.
Derynck, Mika
Lauchle, Jennifer O.
Koeppen, Hartmut
Fredrickson, Jill
Ware, Joseph
Hampton, Garret
Yan, Yibing
Lackner, Mark R.
[J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
[3] Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors
Jia, Hong
Dai, Guangxiu
Su, Weiguo
Xiao, Kun
Weng, Jianyang
Zhang, Zhulin
Wang, Qing
Yuan, Tianhai
Shi, Fuying
Zhang, Zheng
Chen, Wei
Sai, Yang
Wang, Jian
Li, Xiong
Cai, Yu
Yu, Jun
Ren, Ping
Venable, Jennifer
Rao, Tadimeti
Edwards, James P.
Bembenek, Scott D.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (10) : 4936 - 4948
[4] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Chen, Jiezhong
Zhao, Kong-Nan
Li, Rui
Shao, Renfu
Chen, Chen
[J]. CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
[5] Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
Rewcastle, Gordon W.
Kolekar, Sharada
Buchanan, Christina M.
Gamage, Swarna A.
Giddens, Anna C.
Tsang, Kit Y.
Kendall, Jackie D.
Singh, Ripudaman
Lee, Woo-Jeong
Smith, Greg C.
Han, Weiping
Matthews, David J.
Denny, William A.
Shepherd, Peter R.
Jamieson, Stephen M. F.
[J]. ONCOTARGET, 2017, 8 (29) : 47725 - 47740
[6] Designing selective PI3K inhibitors
Sarah Crunkhorn
[J]. Nature Reviews Drug Discovery, 2010, 9 : 105 - 105
[7] Designing selective PI3K inhibitors
Crunkhorn, Sarah
[J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (02) : 105 - 105
[8] Selective PI3K and dual PI3K/mTOR inhibitors enhance the efficacy of endocrine therapies in breast cancer models
Friedman, L.
Ross, L. B.
Wallin, J.
Guan, J.
Prior, W. W.
Wu, E.
Nannini, M.
Sampath, D.
[J]. CANCER RESEARCH, 2012, 72
[9] THE ROLE OF CDK AND PI3K/MTOR INHIBITORS
Andre, Fabrice
[J]. BREAST, 2015, 24 : S25 - S25
[10] Predictive and pharmacodynamic (PD) markers of PI3K pathway inhibitors: focus on PI3K, AKT and mTOR inhibitors
Tabernero, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S6 - S6

← 1 2 3 4 5 →